High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement

• Main Authors: Suryanti S, Agustina H, Aziz A, Yulianti H, Suryawathy B, Putri L
• Format: Article
• Language: English
• Published: Dove Medical Press 2021-08-01
• Series: Research and Reports in Urology
• Subjects: clear cell renal cell carcinoma; cyclooxygenase-2; metastasis; programmed death ligand-1
• Online Access: https://www.dovepress.com/high-immunoexpression-of-cox-2-as-a-metastatic-risk-factor-in-ccrcc-wi-peer-reviewed-fulltext-article-RRU

Sri Suryanti, Hasrayati Agustina, Afiati Aziz, Herry Yulianti, Bethy Suryawathy, Lestari Putri Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin Hospital, Bandung, IndonesiaCorrespondence: Lestari PutriDepartment of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Jl. Pasteur No. 38, Bandung, 40161, IndonesiaTel [phone]Fax [phone]Email [e-mail]: Clear cell renal cell carcinoma (ccRCC) is the most lethal type of malignancy of the urinary tract system as it is resistant to chemotherapy and radiation and has a survival rate of less than 5% in cases of metastasis. Inflammation plays an essential role in the metastasis of ccRCC. Cyclooxygenase-2 (COX-2) is an inflammatory protein that affects the processes of carcinogenesis, invasion, migration, metastasis, and angiogenesis. COX-2 can modulate programmed death ligand-1 (PD-L1) expression and play a role in immune evasion, meaning that tumor cells are able to escape the body’s immune response and more easily metastasize.Purpose: This study aims to determine the role of COX-2 and PD-L1 in the occurrence of ccRCC metastases.Materials and Methods: This study is an observational analytical study, which employed a cross-sectional approach to examine the paraffin block samples of 40 ccRCC cases from Dr. Hasan Sadikin Hospital Bandung, Indonesia, between 2014 and 2021. Immunoexpression was measured using immunohistochemical staining for COX-2 in tumor cells and for PD-L1 in immune cells. PD-L1 calculation was measured using Qupath 0.2.3. digital software. Metastatic data were obtained using radiological imaging and pathological examinations. Meanwhile, the data were analyzed using the chi-square test for COX-2 and Fischer’s exact test for PD-L1.Results: The research results revealed a significant association between COX-2 and the occurrence of metastases in ccRCC (p=0.001) with a prevalence odds ratio of 10.28. Positive PD-L1 immunoexpression of the immune cells (≥ 1%) was found in 14% (3/21) of the metastatic group and 5% (1/19) of the non-metastatic group (p=0.607). There was no association between COX-2 and PD-L1 immunoexpression (p=0.278).Conclusion: This study shows that metastases in ccRCC patients are ten times as likely to be associated with high COX-2 immunoexpression than low COX-2 immunoexpression. COX-2 plays a role in the process of ccRCC metastasis without PD-L1 involvement.Keywords: clear cell renal cell carcinoma, cyclooxygenase-2, metastasis, programmed death ligand-1